The Oslo-listed company reported Q2 adjusted EBITDA of NOK 27.2 million, expanded U.S. blue-light cystoscopy accounts by 20%, and pointed to FDA reclassification and the Vesica Health acquisition as growth catalysts.
verifying reliability
No specialized terms available for this topic.